NASDAQ · KYMR
Healthcare · Biotechnology
$127.09
Up+$5.10 (+4.01%)
Updated Nov 4, 2026, 6:04 PM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · KYMR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
KYMR closed at $127.09 after 21 trading sessions, up 19.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $128.79 | $133.875 | $126.485 | $127.09 | 1.4M |
| Nov 2, 2026 | $127.00 | $129.34 | $124.3001 | $127.51 | 1.29M |
| Oct 30, 2026 | $122.58 | $127.26 | $117.3092 | $126.63 | 1.59M |
| Oct 29, 2026 | $127.00 | $127.74 | $117.74 | $122.60 | 1.05M |
| Oct 28, 2026 | $116.17 | $122.91 | $115.46 | $122.51 | 768.15K |
| Oct 27, 2026 | $114.52 | $119.68 | $111.145 | $117.57 | 828.87K |
| Oct 26, 2026 | $111.96 | $115.22 | $110.312 | $114.84 | 438.58K |
| Oct 23, 2026 | $110.85 | $111.825 | $109.05 | $110.76 | 517.06K |
| Oct 22, 2026 | $111.43 | $113.74 | $110.13 | $110.85 | 850.27K |
| Oct 21, 2026 | $113.38 | $115.75 | $112.52 | $112.63 | 1.06M |
| Oct 20, 2026 | $108.75 | $115.28 | $108.49 | $113.46 | 705.16K |
| Oct 19, 2026 | $106.56 | $109.16 | $105.10 | $108.07 | 683.37K |
| Oct 16, 2026 | $108.19 | $108.59 | $104.39 | $104.78 | 489.33K |
| Oct 15, 2026 | $106.75 | $110.68 | $104.625 | $108.14 | 820.99K |
| Oct 14, 2026 | $106.39 | $108.08 | $105.58 | $106.83 | 1.03M |
| Oct 13, 2026 | $110.83 | $112.06 | $106.5201 | $106.68 | 780.41K |
| Oct 12, 2026 | $111.61 | $113.13 | $110.52 | $112.08 | 537.52K |
| Oct 9, 2026 | $109.54 | $115.815 | $107.4569 | $112.40 | 1.31M |
| Oct 8, 2026 | $106.52 | $110.04 | $104.19 | $109.30 | 1.04M |
| Oct 7, 2026 | $104.58 | $108.68 | $103.45 | $108.35 | 1.17M |
| Oct 6, 2026 | $111.03 | $111.0354 | $101.745 | $105.98 | 960.71K |
The latest Smart Investors Daily articles mentioning KYMR.
Company
Market Activity
Research & News
KYMR research
Company profile and research snapshot.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Barclays | Overweight | — |
| Oct 30, 2026 | RBC Capital | Sector Perform | — |
| Oct 30, 2026 | Truist Securities | Buy | — |
| Oct 29, 2026 | BTIG | Buy | — |
| Oct 27, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Benzinga · Oct 30, 2026
Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.
Benzinga · Oct 30, 2026
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.
Yahoo · Oct 29, 2026
Moby summary of Kymera Therapeutics, Inc.'s Q3 2026 earnings call
Yahoo · Oct 29, 2026
KT-579 IRF5 degrader hit 94% degradation in Phase I trials.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KYMR.
